Moderna Reports Mixed Q4 Earnings, Misses EPS Estimates
Key Points:
* Moderna's (MRNA) Q4 revenue of $966 million exceeds Wall Street expectations of $954 million.
* Full-year revenue reaches $3.2 billion, meeting analysts' estimates.
* Loss per share (LPS) misses estimates: $2.91 reported vs. $2.75 expected for Q4; $9.28 reported vs. $9.17 expected for full year.
* COVID-19 vaccine Spikevax drives revenue, contributing $3.1 billion.
* RSV vaccine generates $15 million in revenue.
* One-time charge and lower prior-year sales contribute to losses.
* CEO Stéphane Bancel outlines cost reduction plans and clinical pipeline expansion goals.
* Uncertainty surrounding Robert F. Kennedy Jr.'s potential impact as HHS head raises concerns.
* Stock remains stable following Kennedy's confirmation.
* Bank of America analysts anticipate discussions on 2025 guidance, HHS implications, clinical catalysts, and upcoming launches during earnings call.